PROGRESS Trial Expands TAVR Evidence to Moderate AS, But Valuation Limits Upside

What happened

Edwards Lifesciences announced positive results from the PROGRESS Trial, showing TAVR superior to clinical surveillance in the composite endpoint of death or heart failure events at two years for moderate aortic stenosis patients with at-risk features. This represents an early-stage indication expansion beyond the currently approved severe symptomatic and asymptomatic AS, potentially enlarging the addressable market for SAPIEN. The data align with Edwards' strategy of extending TAVR into earlier and younger patients, building on recent guideline shifts and EARLY TAVR data. However, the trial was presented at a medical meeting with details not yet fully published, and adoption will require guideline endorsement and payer coverage, which may take time. While this supports the long-term growth narrative, the stock already trades at ~28-29x 2026 EPS, suggesting the market has partially priced in such expansion.

Implication

The trial outcome adds another potential growth vector for TAVR by targeting moderate AS patients, a population not previously served by TAVR in routine practice. However, the path from trial results to widespread commercial use is uncertain, as guidelines and payers will need to endorse the new indication, and competitors may respond with their own trials. Current valuation at ~$85 assumes high-single-digit TAVR growth and successful TMTT scaling, leaving limited room for error. Investors should monitor upcoming ACC/ESC guideline updates and real-world adoption data over the next 6-12 months to confirm the incremental revenue impact. Until then, the stock remains a hold rather than a buy, with the trial serving as a positive but not transformative catalyst.

Thesis delta

The trial moderately strengthens the bull case by expanding the TAVR-addressable population into moderate AS with risk factors, supporting higher long-term volume growth. However, this prospect is largely incremental to existing guidance and may not fully materialize until guidelines and reimbursement align. The WAIT rating remains appropriate given the rich valuation and execution risks, though the probability of achieving base-case growth increases slightly.